BR112016010072A8 - conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado - Google Patents
conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado Download PDFInfo
- Publication number
- BR112016010072A8 BR112016010072A8 BR112016010072A BR112016010072A BR112016010072A8 BR 112016010072 A8 BR112016010072 A8 BR 112016010072A8 BR 112016010072 A BR112016010072 A BR 112016010072A BR 112016010072 A BR112016010072 A BR 112016010072A BR 112016010072 A8 BR112016010072 A8 BR 112016010072A8
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- pharmaceutical composition
- fragmented
- polysaccharide
- making
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
a invenção refere-se a um conjugado com base em polissacarídeo de vi que é fragmentado e uma proteína carreadora, a composições compreendendo o dito conjugado e a métodos para fabricação de dos ditos conjugados e as composições.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20130192176 EP2870974A1 (en) | 2013-11-08 | 2013-11-08 | Salmonella conjugate vaccines |
EP13192176.9 | 2013-11-08 | ||
PCT/IB2014/065869 WO2015068129A1 (en) | 2013-11-08 | 2014-11-07 | Salmonella conjugate vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016010072A8 true BR112016010072A8 (pt) | 2020-04-14 |
BR112016010072B1 BR112016010072B1 (pt) | 2021-06-08 |
Family
ID=49551548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016010072-7A BR112016010072B1 (pt) | 2013-11-08 | 2014-11-07 | conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado |
Country Status (15)
Country | Link |
---|---|
US (1) | US10098947B2 (pt) |
EP (2) | EP2870974A1 (pt) |
JP (1) | JP6289632B2 (pt) |
KR (2) | KR20160079874A (pt) |
CN (1) | CN105828839B (pt) |
AU (1) | AU2014347722B2 (pt) |
BR (1) | BR112016010072B1 (pt) |
CA (1) | CA2929114C (pt) |
EA (1) | EA033491B1 (pt) |
ES (1) | ES2828039T3 (pt) |
IL (1) | IL245217B (pt) |
MX (1) | MX358829B (pt) |
SG (1) | SG11201603306TA (pt) |
WO (1) | WO2015068129A1 (pt) |
ZA (1) | ZA201602834B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017234319B2 (en) * | 2016-03-15 | 2021-11-04 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel polysaccharide-protein conjugates and process to obtain thereof |
BE1025210B1 (fr) * | 2016-11-25 | 2018-12-12 | Glaxosmithkline Biologicals Sa | Conjugues immunogenes et leur utilisation |
MX2021005500A (es) * | 2018-11-10 | 2021-09-08 | Bharat Biotech Int Ltd | Composiciones inmunogenicas de glicoconjugados multivalentes. |
SG11202110303XA (en) * | 2019-03-18 | 2021-10-28 | Janssen Pharmaceuticals Inc | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
CN110018253A (zh) * | 2019-04-15 | 2019-07-16 | 艾美卫信生物药业(浙江)有限公司 | 一种生物制品中游离蛋白含量的高效液相测定方法 |
US20220387614A1 (en) | 2019-11-22 | 2022-12-08 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
KR102493192B1 (ko) * | 2021-07-20 | 2023-01-30 | 에스케이바이오사이언스(주) | 살모넬라 타이피 유래의 피막 다당류-단백질 접합체를 포함하는 백신 조성물 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
IT1214609B (it) * | 1985-05-17 | 1990-01-18 | Opocrin Spa | Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono. |
US4874854A (en) * | 1985-10-08 | 1989-10-17 | Merck & Co., Inc. | Low viscosity heteropolysaccharides |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
JP2921574B2 (ja) * | 1988-02-01 | 1999-07-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンの担体分子としてのt細胞のエピトープ |
US5204098A (en) * | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
SG46492A1 (en) | 1991-03-01 | 1998-02-20 | Minnesota Mining & Mfg | 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
FR2682388B1 (fr) | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5736146A (en) * | 1992-07-30 | 1998-04-07 | Yeda Research And Development Co. Ltd. | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them |
IL102687A (en) * | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
ATE204762T1 (de) | 1993-03-23 | 2001-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
ATE195735T1 (de) | 1993-07-15 | 2000-09-15 | Minnesota Mining & Mfg | Imidazo (4,5-c)pyridin-4-amine |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
IL109790A0 (en) * | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5872246A (en) * | 1994-10-17 | 1999-02-16 | Aqualon Company | Ethyl guar |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
AU725279B2 (en) * | 1995-06-07 | 2000-10-12 | Alberta Research Council Inc. | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them |
DE69841122D1 (de) | 1997-03-10 | 2009-10-15 | Coley Pharm Gmbh | Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
JPH1119664A (ja) * | 1997-07-04 | 1999-01-26 | Kazuyoshi Matsunaga | 酸化ジルコニウム/第二鉄塩/過酸化水素/紫外線系による難生物分解性有機物の分解とリンの除去法 |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
ATE276199T1 (de) | 1999-02-03 | 2004-10-15 | Biosante Pharmaceuticals Inc | Methoden zur herstellung von therapeutische kalzium-phosphat partikeln |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
NZ517929A (en) | 1999-09-25 | 2004-02-27 | Univ Iowa Res Found | Immunostimulatory nucleic acids |
US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
US6756383B2 (en) | 2000-09-01 | 2004-06-29 | Chiron Corporation | Heterocyclic derivatives of quinolinone benimidazoles |
ATE386736T1 (de) | 2000-09-11 | 2008-03-15 | Novartis Vaccines & Diagnostic | Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
CN1300165C (zh) | 2001-11-27 | 2007-02-14 | 安那迪斯药品股份有限公司 | 3-β-呋喃核糖基噻唑并[4,5-d]嘧啶核苷及其应用 |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
CA2480638C (en) | 2002-03-29 | 2013-02-12 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
EP1511746A2 (en) | 2002-05-29 | 2005-03-09 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
JP2006501243A (ja) | 2002-08-23 | 2006-01-12 | カイロン コーポレイション | グリコーゲンシンターゼキナーゼ3のピロールベースのインヒビター |
BR0316271A (pt) * | 2002-11-14 | 2005-10-11 | Inst Finlay Ct De Investigacio | Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma |
CN1404873A (zh) * | 2002-11-22 | 2003-03-26 | 北京绿竹生物技术有限责任公司 | 一种伤寒疫苗 |
WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
ES2391770T3 (es) | 2003-01-21 | 2012-11-29 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos de triptantrina para la potenciación inmune |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
EP1608369B1 (en) | 2003-03-28 | 2013-06-26 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
BRPI0413309B8 (pt) * | 2003-08-06 | 2021-05-25 | The Government Of The Us Secretary Department Of Health And Human Services | método para a preparação de uma vacina conjugada de polissacarídeo-proteína |
CN1934127B (zh) * | 2003-12-17 | 2015-08-19 | 杨森阿尔茨海默氏症免疫治疗公司 | Αβ免疫原性肽载体-偶联物及其生产方法 |
KR20070008625A (ko) | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
GB0810894D0 (en) * | 2008-06-13 | 2008-07-23 | Novartis Vaccines & Diagnostic | Conjugated saccharide |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
GB201003924D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
-
2013
- 2013-11-08 EP EP20130192176 patent/EP2870974A1/en not_active Ceased
-
2014
- 2014-11-07 EA EA201690857A patent/EA033491B1/ru not_active IP Right Cessation
- 2014-11-07 AU AU2014347722A patent/AU2014347722B2/en active Active
- 2014-11-07 MX MX2016006001A patent/MX358829B/es active IP Right Grant
- 2014-11-07 JP JP2016528102A patent/JP6289632B2/ja active Active
- 2014-11-07 CA CA2929114A patent/CA2929114C/en active Active
- 2014-11-07 EP EP14799018.8A patent/EP3065781B1/en active Active
- 2014-11-07 ES ES14799018T patent/ES2828039T3/es active Active
- 2014-11-07 KR KR1020167014954A patent/KR20160079874A/ko active IP Right Grant
- 2014-11-07 BR BR112016010072-7A patent/BR112016010072B1/pt active IP Right Grant
- 2014-11-07 CN CN201480061264.6A patent/CN105828839B/zh active Active
- 2014-11-07 SG SG11201603306TA patent/SG11201603306TA/en unknown
- 2014-11-07 WO PCT/IB2014/065869 patent/WO2015068129A1/en active Application Filing
- 2014-11-07 US US15/033,946 patent/US10098947B2/en active Active
- 2014-11-07 KR KR1020197003712A patent/KR102112663B1/ko active IP Right Grant
-
2016
- 2016-04-20 IL IL245217A patent/IL245217B/en active IP Right Grant
- 2016-04-25 ZA ZA2016/02834A patent/ZA201602834B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN105828839B (zh) | 2020-02-14 |
MX2016006001A (es) | 2016-07-22 |
ZA201602834B (en) | 2020-01-29 |
BR112016010072B1 (pt) | 2021-06-08 |
KR20190015641A (ko) | 2019-02-13 |
EA201690857A1 (ru) | 2016-10-31 |
IL245217B (en) | 2021-03-25 |
US20160263213A1 (en) | 2016-09-15 |
SG11201603306TA (en) | 2016-05-30 |
EP2870974A1 (en) | 2015-05-13 |
EP3065781A1 (en) | 2016-09-14 |
EA033491B1 (ru) | 2019-10-31 |
JP2016536317A (ja) | 2016-11-24 |
KR20160079874A (ko) | 2016-07-06 |
CA2929114C (en) | 2023-08-22 |
ES2828039T3 (es) | 2021-05-25 |
KR102112663B1 (ko) | 2020-05-19 |
MX358829B (es) | 2018-09-05 |
EP3065781B1 (en) | 2020-08-05 |
IL245217A0 (en) | 2016-06-30 |
AU2014347722B2 (en) | 2017-10-26 |
JP6289632B2 (ja) | 2018-03-07 |
AU2014347722A1 (en) | 2016-06-02 |
CA2929114A1 (en) | 2015-05-14 |
US10098947B2 (en) | 2018-10-16 |
CN105828839A (zh) | 2016-08-03 |
WO2015068129A1 (en) | 2015-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016010072A8 (pt) | conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado | |
BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
BR112017023872A2 (pt) | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos | |
BR112015019909A2 (pt) | Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit | |
BR112015031073A2 (pt) | inibidores bicíclicos de bromodomínio | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
BR112017013661A8 (pt) | Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
BR112015030514A2 (pt) | Composições e métodos para conjugação de anticorpos ativáveis | |
BR112015024674A2 (pt) | método para aumentar a capacidade de sobrevivência de um ou mais microrganismos benéficos e para revestir uma semente, e, composição | |
BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
BR112015015870A2 (pt) | composição farmacêutica | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
BR112018000632A8 (pt) | Moléculas de anticorpo que ligam a cd79 | |
BR112016009669A8 (pt) | produtos farmacêuticos, método para tratar câncer e uso de um composto | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
BR112015015858A8 (pt) | composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
BR112016023851A2 (pt) | ?composição de revestimento de duas partes e método para revestir uma superfície? | |
BR112014030655A8 (pt) | Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende | |
CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
BR112017005997A2 (pt) | método | |
BR112018011526A2 (pt) | compostos policíclicos como inibidores da tirosina quinase de bruton | |
BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
CL2015001772A1 (es) | Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma. | |
BR112016030172A2 (pt) | aptâmeros específicos para tlr-4 e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 31/04 (2006.01) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2014, OBSERVADAS AS CONDICOES LEGAIS. |